Patients undergoing transcatheter aortic valve implantation (TAVI) who receive the Evolut valve have significantly lower rates of clinical and subclinical thrombosis, as well as hemodynamic measures, compared with patients who receive the SAPIEN valve, 3-year results from the SMART trial show.